983 related articles for article (PubMed ID: 18204174)
1. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
2. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
4. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
5. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
7. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
[TBL] [Abstract][Full Text] [Related]
8. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).
Dettori AG; Tagliaferri A; Dall'Aglio E; Pini M
Int Angiol; 1988; 7(3 Suppl):7-18. PubMed ID: 2850327
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
11. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
13. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
Romeo G; Salanitri G; Catania G
Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
[TBL] [Abstract][Full Text] [Related]
14. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
Imberti D; Legnani C; Baldini E; Cini M; Nicolini A; Guerra M; De Paoli M; Zanardi A; Palareti G
Thromb Res; 2009 Dec; 124(6):667-71. PubMed ID: 19482341
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
Millet J; Jouault SC; Mauray S; Theveniaux J; Sternberg C; Boisson Vidal C; Fischer AM
Thromb Haemost; 1999 Mar; 81(3):391-5. PubMed ID: 10102467
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
[TBL] [Abstract][Full Text] [Related]
20. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
